An international collaboration of researchers, sponsored by GSK and working on behalf of the ANCHOR-1 and ANCHOR-2 trial ...

Positive results from the Tezspire phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps: Cambridge, UK Tuesday, March 4, 2025, ...

US FDA accepts for review GSK’s BLA for depemokimab for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps: London, UK Tuesday, March 4, 2025, 09:0 ...

GSK plc (GSK) has announced on Monday that the FDA has accepted its Biologics License Application (BLA) for depemokimab for regulatory review in two indications.The proposed ...

GSK, Amgen and AstraZeneca released positive data supporting their rival drugs in a condition called chronic rhinosinusitis ...

"Amgen and AstraZeneca report results from Phase III trial of Tezspire for CRSwNP" was originally created and published by ...

In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, ...

Secondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.

FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.